ReviewMaterials today. Bio2026
T cell-inspired therapeutic delivery platforms: From nanomedicines to cell therapy.
Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nanoparticle-enabled CD40 silencing programs immune tolerance via a DC-Treg-Breg axis in autoimmune myocarditis.Materials today. Bio · 2026Article
- Overcoming chemotherapy resistance in diffuse large B-cell lymphoma using multifunctional nanocarriers: current advances and clinical challenges.Discover nano · 2026Review
- Nature-Inspired Alternatives to PEG for Next-Generation Long-Circulating Nanocarriers.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted nanodrug delivery has garnered significant interest as a carrier for drugs, genes, and vaccines. Despite their clinical potential, these nanocarriers face substantial challenges due to their exogenous nature. These challenges can be addressed by employing T cell-inspired approaches for targeted therapies. T cell-inspired approaches-including T cell membrane-coated nanoparticles, T cell-derived exosomes, T cell hitchhiking, and chimeric antigen receptor (CAR)-T cells-exhibit remarkable properties such as inherent biocompatibility and biodegradability, prolonged circulation lifespan, and the ability to traverse biological barriers. Utilizing T cells as delivery vehicles enables prolonged circulation time and targeted drug transport, along with reduced toxicity to cells and tissues. This review explores innovative T cell-derived approaches, including T cell membrane-coated nanoparticles, T cell-derived exosomes, T cell hitchhiking, and CAR-T cells. We discuss how these methods improve biodistribution, tissue penetration, and immune evasion while preserving T cell functionality in cancer therapies, autoimmune disorders, cardiovascular diseases, and infectious diseases. By comparing conventional nanomedicine approaches with emerging T cell-based delivery systems, this review explores the transformative capability of T cell-inspired delivery in enhancing therapeutic outcomes. Finally, we address current limitations and future directions, including advanced engineering techniques, which could further refine this promising approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.